To the Editor Dr Himelstein and colleagues1 found that the use of zoledronic acid every 12 weeks compared with the standard dosing interval of 4 weeks did not result in an increased risk of skeletal events over 2 years in patients with bone metastases. The randomized, open-label clinical trial included 855 patients with breast cancer, 689 with prostate cancer, and 278 with multiple myeloma, broadening the potential applicability of the findings. Although the authors concluded that this longer interval may be an acceptable treatment option, we would like to raise a concern about applying the study results to patients with multiple myeloma.
Tanimoto T, Tsuda K, Mori J. Zoledronic Acid Dosing Interval for Metastatic Cancer. JAMA. 2017;317(14):1477. doi:https://doi.org/10.1001/jama.2017.2558
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: